Glioblastoma (GBM) is an angiogenic malignancy with a highly unfavorable prognosis. Angiogenesis in GBM represents an adaptation to a hypoxic microenvironment and is correlated with tumor growth, invasion, clinical recurrence, and lethality. LBH589 (also called panobinostat) is a histone deacetylase (HDAC) inhibitor with potent antitumor activity. In the current study, we investigated the mechanism and effects of LBH589 on GBM growth and hypoxia-induced angiogenesis in vitro and in vivo. To determine the antitumor and angiogenesis activity and mechanism of LBH589, we used cell proliferations in vitro and GBM xenografts in vivo. To clarify mechanisms of LBH589 on angiogenesis, HDAC assay, RT-PCR, Western blot, and co-immunoprecipitation assays were performed. We found LBH589 displayed significant antitumor effects on GBM as demonstrated by inhibited cell proliferation, slower tumor growth, and decreased microvessel density of subcutaneous xenografts. These actions of LBH589 resulted from the disruption of heat shock protein 90/HDAC6 complex, increased HIF-1a instability and degradation, and decreased VEGF expression. Our results indicate the potential antiangiogenic activity of LBH589 in human GBM and provide some preclinical data to warrant further exploration of HDAC inhibitors for the treatment of advanced glioma. Moreover, our study supports the role of HDAC inhibitors as a therapeutic strategy to target tumor angiogenesis.
INTRODUCTION
Glioblastoma (GBM) is the most common and aggressive primary brain tumor, with a median overall survival of only 10-14 months (1) . Despite decades of research into its treatment, prognosis remains poor, with only 3%-5% of patients surviving >3 years (2) . Treatment of GBM consists of maximal surgical resection, radiotherapy, and adjuvant chemotherapy with temozolomide (3) . Regardless of multimodality treatment, recurrence or progression of disease is inevitable and uniformly fatal. Therefore, it is necessary to develop effective, novel therapies for GBM.
Angiogenesis is one of the key features of GBM. Neoangiogenesis of GBM is a crucial factor in their growth, aggressive behavior, clinical recurrence, and prognosis of patients (4) . Hypoxia-inducible factor 1 (HIF-1) is an important transcription factor that responses to hypoxia to regulate angiogenesis, cellular survival, and tumor invasion (5) . As a subunit of HIF-1, HIF-1a is responsible to its oxygen sensitivity, determining the availability of HIF-1. HIF-1 activates a large battery of genes, including vascular endothelial growth factor (VEGF), a highly potent cytokine known to promote angiogenesis and increase oxygen delivery to hypoxic regions (6) . Recently, HIF-1a and its signaling pathway have become targets for GBM chemotherapy aimed at inhibiting angiogenesis (7) . For example, it has been demonstrated that histone deacetylase (HDAC) 6 contributed to HIF-1a stability indirectly through deacetylation of heat shock protein (Hsp) 90, which enhanced the Hsp90 chaperone function toward its client proteins, including HIF-1a (8, 9) . Therefore, we speculated HDAC inhibitors might inhibit the deacetylase activity of HDAC6 and indirectly decrease HIF-1a expression through Hsp90/HDAC6-HIF-1a pathway.
LBH589 is a hydroxamic acid and shows its potent inhibitory activity against all class I (including HDAC1, 2, 3, 8) , II (including HDAC4, 5, 6, 7, 9, 10) , and IV (HDAC11) purified recombinant HDAC enzymes at low nanomolar concentrations (10) . LBH589 was also at least 10-fold more potent as a HDAC inhibitory compared with vorinostat, which showed antitumor activity in GBM as a pan-HDAC inhibitor (10, 11) . So far, cotreatments or single-drug treatments with LBH589 exhibited significantly in vitro and in vivo antitumor effects across a variety of hematologic malignancies and solid tumors, including diffuse large B-cell lymphoma, Hodgkin lymphoma, multiple myeloma, pancreatic cancer, and nonsmall cell lung cancer (12) (13) (14) . However, the effect of LBH589 on GBM has not been reported in preclinical studies.
In this study, we detected the antitumor activity of LBH589 in vitro and in vivo against human GBM U87MG and U251MG cells using either cell proliferation assay or nude mouse xenograft model. The correlation between deacetylation activity of LBH589 and its effects on tumor growth and angiogenesis was also evaluated in vitro and in vivo.
MATERIALS AND METHODS

Cell Culture and Reagents
The U87MG and U251MG human GBM cell lines were purchased from R&S Biotechnology Co., Ltd. (Shanghai, China) and cultured in DMEM medium (Gibco BRL, Gaithersburg, MD) with 10% fetal bovine serum. For normoxic conditions, cells were incubated in an atmosphere of 5% CO 2 and 20% O 2 . For hypoxic treatment, the cells were incubated in an atmosphere of 1% O 2 , 5% CO 2 , and 94% N 2 under intermittent flushing with nitrogen. LBH589 was obtained from Selleck Chemicals (Shanghai, China) and dissolved in dimethyl sulfoxide (DMSO) for the preparation of stock solutions (50 mM).
Cell Proliferation Assays
Cell proliferation after treatment with LBH589 at different concentrations (10, 20 , and 40 nM) was measured by CCK-8 assay (Dojindo, Shanghai, China). The U87MG and U251MG cells were seeded at a density of 5 Â 10 4 cells/ 100 mL DMEM/well in 96-well plates and were allowed an overnight period for attachment. Cells were incubated in a humidified incubator under hypoxic conditions at 37 C for 24, 48, and 72 hours. After the designated time, CCK-8 solution was added to each well containing 100 mL of the culture medium and was incubated for another 4-5 hours at 37 C. The amount of formazan dye was measured at 450 nm absorbance using Multiskan MK3 microplate reader (Thermo Scientific, Rockford, IL). All experiments were performed in triplicate and repeated 3 times.
Animal Experiments
Ten 6-week-old male athymic nude C57/BL6J mice (Wanleibio, Shenyang, China) were housed under pathogenfree conditions. All animal studies were done according to the protocol approved by the Animal Care and Use Committee at the Shandong University. U87MG tumor cells (1 Â 10 7 cells in 200 lL medium) were injected subcutaneous into the right flank. The tumor volume was measured using a vernier caliper every 3 days and tumor volumes were calculated using the ellipsoid formula: length Â width Â height Â 0.52 (15) . At 13 days after implantation of tumor cells (tumor volume 100-300 mm 3 ), 5 mice were injected intraperitoneally with LBH589 (20 mg/kg/day). Likewise, the other 5 mice were injected intraperitoneally with DMSO. After injection for 4 weeks, animals were killed and tumor volume and weight were recorded. The tumor tissues were fixed with 10% buffered formalin and embedded in paraffin, then cut into 5-mm-thick sections on glass slides. Paraffin sections were dewaxed and conventional hematoxylin and eosin (H&E) staining was carried out using standard histologic procedures. For immunohistochemistry, dewaxed sections were incubated with primary antibodies against CD34 (1:200, ZSGB-Bio, Beijing, China) overnight at 4 C. Detection of bound antibodies was done using the EnVision System (Dako, Denmark) following the manufacturers' instructions. The microvessel density (MVD) was determined by counting the number of blood vessels stained with the antiCD34 antibody. The MVD for each tumor was expressed as the average count of the 10 most densely stained fields identified in the Â200 field (16) . Each positive endothelial cell cluster of immunoreactivity in contact with the selected field was counted as an individual vessel in addition to the morphologically identifiable vessels with a lumen.
HDAC Activity Assay
HDAC activity assays were performed using the colorimetric HDAC activity assay from BioVision (BioVision, San Francisco, CA) according to manufacturer's instructions and previous described (17) . Briefly, 50 mg of cellular extracts from LBH589 treated hypoxic U87MG and U251MG cells were diluted in 85 mL ddH 2 O; then, 10 mL of 10Â HDAC assay buffer were added followed by additional of 5 mL of the colorimetric substrate; samples were incubated at 37 C for 1 hour. Subsequently, the reaction was stopped by adding 10 mL of lysine developer and left for additional 30 minutes at 37 C. Samples were then quantitated using Multiskan MK3 microplate reader (Thermo Fisher Scientific) at 400 nm. HDAC activity was expressed as relative OD values per mg of protein sample. The kit contains negative and positive controls that consist of nuclear extract of HeLa treated or not with Trichotatin A, respectively.
Quantitative Real-Time Reverse Transcription PCR
Total RNA was extracted from LBH589 treated hypoxic U87MG cells and quantified using RNA Isolation Reagent kit (BioTeke, Beijing, China). cDNA was obtained from 1 mg of total RNA from each sample (Super M-MLV reverse transcriptase, BioTeke) and 1 mL of cDNA sample was used as template for PCR with SYBR Green One Step RT-qPCR Kit (Solarbio, Beijing, China) following the manufacturer's instructions. PCR were carried out in an Exicycler 96 (Bioneer, Dajeon, Korea). For each sample and experiment, triplicates were made and normalized by b-actin mRNA levels. PCR amplification was performed with the following primers:
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Western Blot Analysis and Co-Immunoprecipitation
Total proteins were extracted from LBH589 treated hypoxic U87MG cells using lysis buffer (Beyotime, Wuhan, China). Western blot analyses were carried out according to methods as previously described (18) . The monoclonal or polyclonal antibodies were purchased from Abcam (Cambridge, UK; antibodies against HIF-1a, acetylated lysine, HDAC6, and acetylated H3/H3), Santa Cruz Biotechnology (Santa Cruz, Santa Cruz, CA; antibody against Hsp90). Coimmunoprecipitation was performed as previously described (18) . In brief, cell lysates (500 mg) were incubated with HIF1a, Hsp90, or normal rabbit IgG, or normal mouse IgG monoclonal antibodies (Santa Cruz Biotechnology) for 1 hour, then immunoprecipitated out with Protein A-agarose beads (Santa Cruz Biotechnology) at 4 C overnight. The immunoprecipitates were washed 3 times in the lysis buffer, and proteins were eluted with the SDS sample loading buffer prior to Western blot analyses with specific antibodies against acetylated lysine (Ace-lysine) and HDAC6.
Statistical Analysis
Data were analyzed using SPSS software (SPSS Inc., Chicago, IL). For 2 groups in the animal experiment, the Student's t test was used with equal/unequal variance version depending on variance ratio test. For 3 or more groups, Levene tests were performed to assess variance homogeneity. Standard 1-way ANOVA followed with Student-Newman-Keuls multiple comparison procedures were performed with homogeneous variances, and the Welch's ANOVA followed by Games-Howell multiple comparisons test was performed with heterogeneous variances. A final value of p < 0.05 was considered significant. GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA) was used to generate histograms and line chart.
RESULTS
LBH589 Inhibited Growth of U87MG and U251MG Cells In Vitro and In Vivo
After treatment with serial dilutions (10, 20 , and 40 nM) at different times (24, 48 , and 72 hours), the antitumor activity of LBH589 was assessed in human GBM U87MG and U251MG cell lines. Under phase-contrast microscope, the number of LBH589 treated U87MG cells was significantly decreased at 48 and 72 hours (Fig. 1A) . The CCK-8 assay showed the relative concentration of DMSO ( 0.1%) has little influence on cell proliferation compared with the control group (p > 0.05). However, treatment with LBH589 resulted in significant inhibition of U87MG cell proliferation at concentrations of 20 and 40 nM at both 48 and 72 hours compared with DMSO treatment (Fig. 1B) . In detail, after LBH589 treatment for 40 nM, the OD values were decreased by 57.6% (p ¼ 0.000) and 52.2% (p ¼ 0.000) at 48 and 72 hours, respectively. On the basis of the growth inhibition assay, the IC50 of LBH589 treatment at 48 and 72 hours was calculated to be 35 nM and 50 nM in U87MG cells. However, no significant inhibition of U87MG cells proliferation was observed after 24 hours treatment of LBH589 (p > 0.05). These results showed LBH589 inhibited U87MG cells proliferation.
We also detected the effect of LBH589 on the proliferation of U251MG cells. The densities of cells were also significantly decreased at 48 and 72 hours (Fig. 1A) . After 24 hours, the OD value were significantly decreased by 30.0% for 40 nM group compared with DMSO treatment (p ¼ 0.000, Fig. 1C ). After treatment with LBH589 for 48 and 72 hours at 3 concentrations (10, 20, and 40 nM), U251MG cell proliferations were significantly inhibited compared with DMSO treatment (p < 0.01, Fig. 1C ). For example, the OD values at 40 nM groups were decreased by 29.5% at 48 (p ¼ 0.000) and 72 hours (p ¼ 0.000). Our results also displayed LBH589 inhibited U251MG cells proliferation.
Nude mice bearing U87MG xenografts were treated intraperitoneally with LBH589 (20 mg/kg/day) beginning on day 13 after tumor implantation. The tumor volume was significantly smaller from the day 25 than controls that had received DMSO (p < 0.01, Fig. 2A, B) . On day 42, LBH589 suppressed tumor growth by 53.1% (p ¼ 0.001) in volume. These data indicate that LBH589 inhibited tumor growth in vivo.
LBH589 Inhibited Angiogenesis in U87MG Xenografts
We detected the MVD in the tumor tissues from the U87MG xenograft mice. Immunohistochemical staining using antibody against CD34 showed the MVD in the solid areas of the tumor was significantly reduced by 63.0% in LBH589 treatment group (p ¼ 0.001, Fig. 3A, C) . H&E staining showed significant tumor necrosis in both groups. Moreover, H&E staining presented numerous dilating blood vessels surrounding necrosis foci in DMSO treated tumors, while only a few vessel fissures were found in LBH589 treated tumors (Fig. 3B) . Immunostaining using antiCD34 antibody showed the MVD surrounding necrosis foci was significantly reduced by 86.1% compared with the DMSO treatment controls (p ¼ 0.000, Fig. 3C ). These results indicated that LBH589 inhibited angiogenesis in U87MG xenografts.
LBH589 Inhibited HDACs Activity in U87MG and U251MG Cells
To investigate whether a decrease in deacetylase activity could be achieved by LBH589 treatment in U87MG and U251MG cells, total HDACs activity was evaluated in cell extracts by colorimetric commercial HDACs activity assay. As shown in Figure 4A We next detected the protein deacetylation level in U87MG cells. As shown in Figure 4B , the acetylation level of histone H3 was increased after LBH589 treatment for 48 hours. The relative levels of acetylated histone 
Mechanisms of LBH589 Inhibited Angiogenesis in U87MG Cells
Considering the important role of HIF-1a and VEGF in angiogenesis of GBM (7), we first detected HIF-1a and VEGF expressions at mRNA and protein levels after LBH589 treatment for 48 hours under hypoxic conditions. Compared with DMSO treatment group, VEGF mRNA expression was reduced by 50.7% in LBH589 treatment group (p ¼ 0.026, Fig. 5A ). However, no significant difference of HIF-1a mRNA level was observed between DMSO and LBH589 treatment groups (p ¼ 0.035). At protein levels, LBH589 treatment significantly reduced HIF-1a and VEGF expressions by 93.8% (p ¼ 0.000) and 75.7% (p ¼ 0.001), respectively (Fig. 5B) . These results suggested HIF-1a may be regulated by LBH589 at the posttranslational level.
Previous studies have demonstrated that HIF-1a degradative pathway was regulated by Hsp90 (19) . Accordingly, co-immunoprecipitation with immunoblotting analysis showed HIF-1a coprecipitated the decreased level of Hsp90 in U87MG cells after LBH589 treatment for 48 hours under hypoxia compared with the DMSO group (Fig. 5C ). However, there was no significant difference of HDAC6 expression between the 2 groups. Second, HDAC6 has been demonstrated to interact with Hsp90 and regulate its acetylation (8) . 
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Therefore, we next determined whether HDAC activity inhibition caused an increase in Hsp90 acetylation. Coimmunoprecipitation with immunoblotting analysis showed Hsp90 coprecipitated with the increased level of acetylated lysine residues (Ace-lysine) and the decreased level of HDAC6 compared with the DMSO group (Fig. 5D ), indicating that Hsp90/HDAC6 complex formation was disrupted by LBH589. However, there was no difference of HDAC6 mRNA or protein expression level between both groups (data not shown). These results showed that LBH589 inhibited HDAC6-mediated deacetylation of Hsp90, resulting in HIF1a instability and degradation.
DISCUSSION
In this study, we found LBH589 significantly inhibited the proliferations of U87MG and U251MG cells in vivo. In addition, LBH589 also significantly suppressed growth of U87MG xenografts in vitro. These results suggest antitumor potency of LBH589 on GBM. GBM is also one of the most highly vascularized human tumors, and its growth and survival is dependent on angiogenesis (4). HIF-1a is one of the best described regulatory gene and transcription factor activated under hypoxia, leading to VEGF transcription and angiogenesis in GBM (20) . VEGF increases vascular endothelial cell proliferation in GBM. Multiple strategies have been developed to target VEGF-mediated angiogenesis (21) . In our study, we found LBH589 inhibited HIF-1a at the protein level rather than the mRNA level under hypoxic conditions. LBH589 inhibited VEGF at both protein and mRNA levels. Therefore, the anti-angiogenesis effect of LBH589 was confirmed by the inhibition of HIF-1a activity and decreased VEGF secretion in our study. Furthermore, Zhong et al found the HIF-1a immunostaining was especially intense in pseudopalisading tumor cells surrounding areas of necrosis in human GBM specimens (22) , suggesting the increased proangiogenic factors surrounding the necrosis foci. Actually, microvascular hyperplasia in the GBM is a form of angiogenesis that is induced by hypoxic pseudopalisading cells and is usually present in regions adjacent to necrosis (23) . Hence, the significantly decreased MVD detected in implanted U87MG xenografts, especially surrounding necrosis foci, provided further evidence that LBH589 inhibits hypoxia-induced angiogenesis in GBM. It has been demonstrated HDAC6 contributed to HIF-1a stability indirectly through deacetylation of Hsp90, which enhanced the Hsp90 chaperone function toward its client proteins, including HIF-1a (8, 9) . On the other hand, in our study, although there was no effect on HDAC6 expression, LBH589 Inhibition of GBM Growth and Angiogenesis significantly inhibited HDAC activity in U87MG and U251MG cells and increased protein acetylation in U87MG cells, suggesting LBH589 may exert its inhibitory effects on GBM through decreased HDAC6 activity. Accordingly, the loss of deacetylation activity of HDAC6 induced by LBH589 increased the level of acetylated Hsp90 detected using coimmunoprecipitation. The hyperacetylation of Hsp90 repressed its chaperone function, leading to the accumulation of immature HIF-1a and degradation mediated by the von Hippel-Lindau (VHL) protein, a tumor suppressor that acted as an ubiquitin ligase (E3) to enhance HIF-1 ubiquitination and proteasomal degradation (24) . Thus, we speculated LBH589 may inhibit angiogenesis through targeting HDAC6 activity in the Hsp90/HDAC6 complex and facilitating HIF-1 degradation (Fig. 6 ). In addition, it has been reported HDAC1, 3, and 4 could directly bound to HIF-1a and induced deacetylation of lysine residues and thus enhanced HIF-1a stability (25, 26) . HDAC7 also cotranslocated to the nucleus with HIF1a under hypoxic conditions and increased transcriptional activity of HIF-1a through the formation of a complex with HIF-1a and p300 (27) . Jeong et al reported that HIF-1a protein was acetylated at the K532 residue by ARD1 (ArrestDefective-1), promoting its interaction with VHL and thus enhancing its ubiquitination and degradation (27) . These findings suggest multiple Class I and Class II HDACs regulate HIF-1a stability as demonstrated in Figure 6 . Thus, it cannot be excluded that LBH589, as a pan-HDAC inhibitor, may also decrease HIF1a levels through simultaneously targeting other HDACs. On the other hand, it has been demonstrated LBH589 inhibited VEGF-induced endothelial cell motility and tube formation detected using human umbilical vein endothelial cells (29) . These results provide evidence that LBH589 might inhibit angiogenesis in GBM through targeting both the tumor and stromal endothelial cell compartments. Thus, further research is needed to understand other pathways which act simultaneously to enhance antiangiogenic effects of LBH589 in GBM.
In conclusion, we found LBH589 inhibited proliferation and angiogenesis of GBM both in vivo and in vitro through increased HIF-1a instability and degradation mediated by Hsp90/HDAC6 complex under hypoxic conditions. Although a recent phase II study reported the addition of LBH589 to bevacizumab did not significantly improve the 6-month progression-fee survival rate of patients with recurrent GBM compared with historical controls of bevacizumab monotherapy (30), we think our study will provide some preclinical data exploring the activity of the LBH589 to potentially improve the therapeutic response for GBM in the future.
